Diabetic Retinopathy Market Size

Summary:

• The global diabetic retinopathy market size reached US$ 8.1 Billion in 2023.
• The market is expected to reach US$ 13.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
• North America leads the market, accounting for the largest diabetic retinopathy market share.
• Non-proliferative retinopathy accounts for the majority of the market share in the type segment because it can be more frequently diagnosed and treated than the more severe proliferative form.
• Anti-VEGF drugs holds the largest share in the diabetic retinopathy industry.
• Hospitals and pharmacies remain a dominant segment in the market because they are the initial points of care (POC) for the administration of treatments and management of diabetic retinopathy.
• The increasing adoption of telemedicine and remote monitoring tools is enhancing access to diabetic retinopathy screenings in underserved and rural areas, driving market growth.
• The global diabetic retinopathy market size is experiencing substantial growth, primarily fueled by the rising prevalence of diabetes and the expanding geriatric population.
• Rising healthcare expenditure and government initiatives aimed at improving diabetic care infrastructure are further boosting the availability of advanced treatments for diabetic retinopathy, accelerating market demand.